Navigation Links
Ceregene Completes Enrollment of Phase 2 Clinical Trial for Parkinson's Disease
Date:11/14/2007

ts. With positive results from the Phase 2 study, we would expect to initiate a Phase 3 trial for CERE-120 in 2009."

"CERE-120 represents a truly revolutionary future treatment option for Parkinson's disease patients, given that a single treatment is not only intended to improve the symptoms of the disease, but also slow disease progression. We appreciate the courage of the patients and the efforts of the physicians who have participated in our Phase 2 trial and hope that CERE-120 may someday provide a meaningful difference in the lives of Parkinson's disease patients. We thank all trial participants for enrolling this study safely and within the projected time frame," stated Raymond T. Bartus, Ph.D., Ceregene's senior vice president of clinical and preclinical R&D and chief operating officer.

About CERE-120

CERE-120 is composed of an adeno-associated virus (AAV) vector carrying the gene for neurturin (NTN), a naturally occurring protein known to repair damaged and dying dopamine-secreting neurons, keeping them alive and functioning normally. NTN is a member of the same protein family as glial cell-derived neurotrophic factor (GDNF). The two molecules have similar pharmacological properties, and both have been shown to benefit the midbrain dopamine neurons that degenerate in Parkinson's disease and are responsible for the major motor impairments. CERE-120 is delivered by stereotactic injection to the affected area of the brain, providing stable, long-lasting expression of NTN in a highly targeted fashion. Genzyme Corporation (Nasdaq: GENZ) has licensed the ex-North American rights for the development and commercialization of CERE-120 from Ceregene, a deal which was announced in June 2007.

About Parkin
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Eligard(R) six-month formulation successfully completes European approval procedure
2. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
3. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
4. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
5. GSI Securitization Completes Merger and Domicile Transfer
6. Medical Services International Inc. Completes Testing for European Union (EU) Application
7. Inverness Completes Acquisition of Cholestech
8. Billians HealthDATA Completes Comprehensive Long Term Care Database Update
9. Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants
10. Explorer completes the map ... for the bodys blueprint
11. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... August 31, 2014 Healthy Grid ... cavities. Loloz lollipops will use herbs to fight ... hard candies will also fight bacteria while stimulating saliva production. ... together,” said Andrew Clapp of Healthy Grid. “Even though personal ... can always use a little more prevention. Cavities are painful ...
(Date:8/31/2014)... CO (PRWEB) August 31, 2014 ... released award winning, “Simplicity & Sophistication: Short Stories ... written and narrated by Dr. James W. Jackson author, ... Sophistication,” Dr. Jackson compresses his vast volume ... four decades into over 150 countries on behalf of ...
(Date:8/31/2014)... 2014: Renal denervation seems to be more successful at ... it includes accessory renal arteries, according to research presented ... Germany. , Dr Schmiedel said: "More than one billion ... as blood pressure (BP) greater than 140/90 mmHg. Up ... and are unable to reduce BP below 140/90 mmHg ...
(Date:8/30/2014)... Sunday 31 August 2014: Local anaesthetic is as safe ... general anaesthetic, according to results of the FRANCE 2 ... Chopard from France. , Dr Chopard said: "Numerous studies ... for patients with severe symptomatic aortic stenosis who are ... aortic valve replacement. The number of TAVI procedures in ...
(Date:8/30/2014)... Not only is USHEALTH Advisors now on pace ... its highest level of late-summer sales, including a new company ... to set a new record in 2014,” stated USHEALTH Advisors ... in both weekly annualized volume and the amount of writing ... August, we saw even more of our agents enjoying tremendous ...
Breaking Medicine News(10 mins):Health News:Healthy Grid: Fight Cavities With Sweet Treats 2Health News:Healthy Grid: Fight Cavities With Sweet Treats 3Health News:Brook Forest Voices Announces End of Summer Release! Dr. James Jackson’s, “Simplicity & Sophistication” Audiobook 2Health News:Renal denervation more successful when it includes accessory arteries 2Health News:Local anesthetic for TAVI as safe and effective as general anesthetic 2Health News:USHEALTH Advisors, LLC Continues Its Record-Setting Sales Pace 2
... For his dedication to advancing the diversity of doctoral-level ... the American Association for the Advancement of Science (AAAS) ... DeSimonewho serves as both the Chancellor,s Eminent Professor of ... Hill (UNC), and as the William R. Kenan, Jr. ...
... (BWH) was selected by the Centers for Medicare & ... a demonstration project that promotes appropriate utilization of advanced ... was selected as a convener under the Medical Imaging ... Medical Center-Physician Hospital Organization; University of Wisconsin Hospital Foundation, ...
... Amanda Gardner HealthDay Reporter , WEDNESDAY, Feb. 16 ... state-of-the-nation,s health report and the news is mixed, with life ... On the positive side, life expectancy was up slightly ... beginning of the decade. And while women are still ...
... the unpredictable economy, nearly three-quarters (73%) of New Jersey ... globally is important to jobs and incomes in the ... Research!America. The poll data will be released today at ... research and development (R&D) experts and New Jersey business, ...
... (HealthDay News) -- Americans living in parts of Appalachia ... active in their free time, according to federal government ... least likely to be physically active during leisure time ... inactivity rates are 29.2 percent or greater for more ...
... , WEDNESDAY, Feb. 16 (HealthDay News) -- Many American parents ... and cold medicines to their kids despite U.S. Food and ... In response to research linking over-the-counter (or OTC) cough and ... ages 2 years and younger, the FDA said in 2008 ...
Cached Medicine News:Health News:2010 AAAS Mentor Award goes to Dr. Joseph M. DeSimone of the University of North Carolina at Chapel Hill, and North Carolina State University 2Health News:2010 AAAS Mentor Award goes to Dr. Joseph M. DeSimone of the University of North Carolina at Chapel Hill, and North Carolina State University 3Health News:2010 AAAS Mentor Award goes to Dr. Joseph M. DeSimone of the University of North Carolina at Chapel Hill, and North Carolina State University 4Health News:Brigham and Women's Hospital selected to participate in Medicare imaging demonstration project 2Health News:Brigham and Women's Hospital selected to participate in Medicare imaging demonstration project 3Health News:America's Health a Mixed Bag: Report 2Health News:America's Health a Mixed Bag: Report 3Health News:Most New Jersey residents see global health as critical to state's economy 2Health News:Most New Jersey residents see global health as critical to state's economy 3Health News:Appalachia, the South Home to Least-Active Americans: CDC 2Health News:Parents Still Giving Cough, Cold Meds to Kids Under 2: Poll 2
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets  has ... Pipeline Insight 2014" report to their offering. ... is one of the largest segments of pharmaceuticals industry. The ... while the available therapies were unable to meet the market ... market for CNS disorder, especially over the past two decades. ...
(Date:8/29/2014)... , Aug. 29, 2014 Research ... "Research and Development Trend Forecast of Pharmaceutical Equipment ... Research and Development Trend Forecast of ... 2014-2018 mainly analyzes China,s pharmaceutical ... supply & demand, competition landscape, and business performance of ...
(Date:8/29/2014)... , August 29, 2014 ... Market by Product & Services (Equipment, Reagent, Primer, ... Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, ... MarketsandMarkets, the global Oligonucleotide Synthesis Market is expected ... Million in 2014, growing at a CAGR of ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4
... Compare Genous vs. Drug-Eluting and Bare ... ... in the,randomized TRIAS (TRI-stent Adjudication Study) trial of OrbusNeich,s,Genous Bio-engineered R ... April, according to Robbert de Winter, M.D., Ph.D.,principal investigator and director ...
... 16 Protocol Driven Healthcare,Inc. (PDHI) today ... Hallmark Insights to provide fully integrated incentive ... ConXus health improvement platform. ConXus Rewards ... points earned by participants completing activities within ...
Cached Medicine Technology:Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) 2PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs 2
... A product you can trust its ... perform retinal, cataract, and glaucoma therapy ... III Combi is the optimal system ... and combined iridotomy. The push of ...
... YAG III is the new disruption ... in particular for applications in posterior ... the YAG laser is also used ... IOL polishing. It's another milestone in ...
... is a top quality Carl Zeiss Meditec ... vision defects even safer, more patient-friendly and ... work platform are oriented towards increasing efficiency, ... recovery of vision. Key factors here are ...
An aid for advancing a pacemaker lead through the subcutaneous tissue of the chest wall to the pacemaker pocket....
Medicine Products: